OOIR: Observatory of International Research

Papers

(The median citation count of Circulation-Heart Failure is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Impact of Multimorbidity on Mortality in Heart Failure With Mildly Reduced and Preserved Ejection Fraction	178
Cognitive and Procedural Competencies in the Cardiac Intensive Care Unit	115
Longitudinal Trends in Donor and Recipient Risk Profile, and Clinical Outcomes, for Donation After Circulatory Death Heart Transplantation	86
National Organ Procurement and Transplant Network Heart Allocation Policy: 6 Years Later	85
Letter by Qiu and Du Regarding Article, “Sodium Restriction in Patients With Heart Failure: A Systematic Review and Meta-Analysis of Randomized Clinical Trials”	81
Characteristics of United States Counties in Which Heart Failure Clinical Trials of Pharmacotherapy Were Conducted	80
Identifying Discordance of Right- and Left-Ventricular Filling Pressures in Patients With Heart Failure by the Clinical Examination	63
Comparing New York Heart Association Class and Patient-Reported Outcomes Among Patients Hospitalized for Heart Failure	60
Prognostic Value of Elevated Levels of Plasma N-Acetylneuraminic Acid in Patients With Heart Failure	60
Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy	59
Mavacamten: Real-World Experience From 22 Months of the Risk Evaluation and Mitigation Strategy (REMS) Program	55
Pitfalls in Using Estimated Glomerular Filtration Rate Slope as a Surrogate for the Effect of Drugs on the Risk of Serious Adverse Renal Outcomes in Clinical Trials of Patients With Heart Failure	53
Impact of Tafamidis and Optimal Background Treatment on Physical Performance in Patients With Transthyretin Amyloid Cardiomyopathy	49
GDMT Optimization, But Make It Patient-Centered: Understanding Patient Needs During Heart Failure Medication Discussions	48
Early Outcomes in Patients With LVAD Undergoing Heart Transplant via Use of the SherpaPak Cardiac Transport System	46
Equity in Heart Failure Care: A Get With the Guidelines Analysis of Between- and Within-Hospital Differences in Care by Sex, Race, Ethnicity, and Insurance	46
Epicardial Fat Paradox and Differential Effects of GLP-1 Receptor Agonists Across Heart Failure Phenotypes	46
Infarct Size Reduction With Cyclosporine A in Circulatory Death Rat Hearts: Reducing Effective Ischemia Time With Therapy During Reperfusion	45
Impact of Insulin Treatment on the Effect of Eplerenone: Insights From the EMPHASIS-HF Trial	44
Association of Pulmonary Artery Pulsatility Index With Adverse Cardiovascular Events Across a Hospital-Based Sample	43
Proposed Cardiac End Points for Clinical Trials in Immunoglobulin Light Chain Amyloidosis: Report From the Amyloidosis Forum Cardiac Working Group	43
Sex-Specific Clinical Outcomes of the PACT-HF Randomized Trial	42
Pseudo-Severe Mitral Stenosis From Obesity-Related HFpEF and Atrial Myopathy	39
Diastolic Perfusion Pressure Predicts Response to Inotropes and Vasopressors and Benefit From Mechanical Circulatory Support in Cardiogenic Shock	38
Myocardial Inflammation in Cardiac Transthyretin Amyloidosis: Prevalence and Potential Prognostic Implications	38

Trajectory of Cognitive Function After Incident Heart Failure	38
Predicted Heart Mass: A Tale of 2 Ventricles	37
Predicting 1-Year Mortality in Outpatients With Heart Failure With Reduced Left Ventricular Ejection Fraction: Do Empiric Models Outperform Physician Intuitive Estimates? A Multicenter Cohort Study	35
ERBB4 and Multiple MicroRNAs That Target ERBB4 Participate in Pregnancy-Related Cardiomyopathy	35
Letter by Baldovino et al Regarding Article, “Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy”	35
Psychometric Evaluation of the Kansas City Cardiomyopathy Questionnaire in Men and Women With Heart Failure	35
Incidence and Outcomes of Advanced Heart Failure in Adults With Congenital Heart Disease	34
Plasma Proteomics of the Fontan Circulation Reveal Signatures of Oxidative Stress and Cell Death	33
Increased Chamber Resting Tone Is a Key Determinant of Left Ventricular Diastolic Dysfunction	32
Long-Term Functional Outcomes in the First 12 Months After VA-ECMO in Adult Patients: A Prospective, Multicenter Study	32
Factors Associated With Racial and Ethnic Diversity Among Heart Failure Trial Participants: A Systematic Bibliometric Review	32
Health-Related Quality of Life in Older Patients With Heart Failure From Before to Early After Advanced Surgical Therapies: Findings From the SUSTAIN-IT Study	31
Failing to Make the Grade: Conventional Cardiac Allograft Rejection Grading Criteria Are Inadequate for Predicting Rejection Severity	31
Rethinking the Nomenclature of Heart Failure Cardiogenic Shock: Do We Need to Start De Novo?	30
Prolonged Extreme Asymptomatic Hypertroponinemia as a Milestone in Diagnosis of Familial Arrhythmogenic Right Ventricular Cardiomyopathy	30
Current Approach to the Diagnosis of Sarcopenia in Heart Failure: A Narrative Review on the Role of Clinical and Imaging Assessments	29
Rethinking Donor and Recipient Risk Matching in Europe and North America: Using Heart Transplant Predictors of Donor and Recipient Risk	29
Ongoing Enigma of NT-proBNP in HFpEF: Insights From Proteomics	29
Correction to: “Polygenic Score for β-Blocker Survival Benefit in European Ancestry Patients With Reduced Ejection Fraction Heart Failure”	28
Use of a Cardiac Scale to Predict Heart Failure Events: Design of SCALE-HF 1	27
Knowing All the Angles (on Right Ventricular Myocardial Remodeling)	26
Pressure Overload–Induced Cardiac Hypertrophy Stimulates Tumor Growth in Tumor-Prone Apc ^Min Mice	25
Hierarchical Analysis of Composite Time-to-Event End Points in Heart Failure Clinical Trials Using Time in Clinical State	24
Response by Prisco and Prins to Letter Regarding Article, “Inflammatory Glycoprotein 130 Signaling Links Changes in Microtubules and Junctophilin-2 to Altered Mitochondrial Metabolism and Right Ventri	24
Assessing Heuristic Bias During Care for Patients Hospitalized for Heart Failure: Get With The Guidelines-Heart Failure	24
Changing Treatment Landscape in Transthyretin Cardiac Amyloidosis	24
Small Endogeneous Peptide Mitigates Myocardial Remodeling in a Mouse Model of Cardioselective Galectin-3 Overexpression	24
When the Whole Is the Sum of Its Parts: Validation of the Heart Failure Collaboratory Medication Composite Score in Denmark	24
Proving SGLT2 Inhibitor-Mediated Improvement in Cardiomyocyte Energetics: Beyond a Reasonable Doubt?	23
Temporal Trends and Clinical Trial Characteristics Associated With the Inclusion of Women in Heart Failure Trial Steering Committees: A Systematic Review	23
Sympathetic Response to 1-Leg Cycling Exercise Predicts Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction	23
Letter by Inker et al Regarding Article, “Pitfalls in Using Estimated Glomerular Filtration Rate Slope as a Surrogate for the Effect of Drugs on the Risk of Serious Adverse Renal Outcomes in Clinical	23
Redefining Cardiac Antibody-Mediated Rejection With Donor-Specific Antibodies and Graft Dysfunction	23
Mucopolysaccharidosis Type IIIA Presenting as Hypertrophic Cardiomyopathy	23
Peripheral Venous Pressure+Fenestration Doppler=Noninvasive Cardiac Catheterization Post-Fontan	23
Absence of Kidney Tubular Injury in Patients With Acute Heart Failure With Acute Kidney Injury	23
Cardiomyopathy Across the Tree of Life: Insights for Clinicians and Investigators	22
Response by Brahmbhatt et al to Letter Regarding Article, “Liberation From Venoarterial Extracorporeal Membrane Oxygenation: A Review”	22
PHM in Heart Transplantation: From Predicted Heart Mass to Practical Heart Matching	22
Letter by Kounis et al Regarding Article, “Biopsy-Proven Giant Cell Myocarditis Following the COVID-19 Vaccine”	22
Trends in Substance Abuse Disorders Among Patients Hospitalized for Heart Failure in the United States	22
Enhancing Sweat Rate Using a Novel Device for the Treatment of Congestion in Heart Failure	21
Yellow Wine Polyphenolic Compound Protects Against Doxorubicin-Induced Cardiotoxicity by Modulating the Composition and Metabolic Function of the Gut Microbiota	21
Race, Social Determinants of Health, and Length of Stay Among Hospitalized Patients With Heart Failure: An Analysis From the Get With The Guidelines-Heart Failure Registry	21
Letter by Lim Regarding Article, “The Pitfalls in the World of Evidence-Based Medicine: Should IABP Be en-DANGER-ed by the Danger Shock Trial?”	21
Targeting Preload in Heart Failure: Splanchnic Nerve Blockade and Beyond	21
Mosaic Loss of the Y Chromosome Is Enriched in Patients With Wild-Type Transthyretin Cardiac Amyloidosis and Associated With Increased Mortality	20
Home-Time, Mortality, and Readmissions Among Patients Hospitalized With Heart Failure: A Baseline Prior to IMPLEMENT-HF	20
Transfer to Hub Hospitals and Outcomes in Cardiogenic Shock	20
NETosis Is an Important Component of Chronic Myocardial Inflammation in Patients With Heart Failure	20

Socioeconomic Disparities Are Associated With Delayed Access to Tafamidis in Transthyretin Cardiac Amyloidosis	20
Race, Sex, and Age Disparities in the Performance of ECG Deep Learning Models Predicting Heart Failure	20
Harnessing the Plasma Proteome to Predict Mortality in Heart Failure Subpopulations	20
Ironing Out the Controversies Surrounding the Iron Deficiency Definition in Heart Failure	20
Uncovering Unrecognized Heart Failure With Preserved Ejection Fraction Among Individuals With Obesity and Dyspnea	20
Relationship Between Cardiac Structure and Function With Renal Function Trajectory and Outcomes in Patients With Heart Failure: Insights From the PARAGON-HF Trial	20
Defining the Specific Skeletal Muscle Adaptations Responsible for Exercise Training Improvements in Heart Failure With Preserved Ejection Fraction	20
Single Arterial Access for VA-ECMO–Assisted Stenting of a Left Ventricular Assist Device Outflow Graft Obstruction in the Setting of an Oversewn Aortic Valve	20
Novel Small-Molecule Troponin Activator Increases Cardiac Contractile Function Without Negative Impact on Energetics	19
Pulsus Alternans in Cardiogenic Shock Recapitulated in Single Cell Fluorescence Imaging of a Patient’s Cardiomyocyte	19
First Bicaval Valve Implantation in a Heart Transplant Patient to Treat Severe Symptomatic Tricuspid Regurgitation	19
Skeletal Muscle Mass Recovery Early After Left Ventricular Assist Device Implantation in Patients With Advanced Systolic Heart Failure	19
SGLT2 Inhibitor–Related Polycythemia in a Patient With Chronic Heart Failure: A Potential Severe Adverse Event	19
Social Determinants of Health and Heart Failure: Clinical Takeaways From 5 Pivotal Analyses of the GWTG-HF Registry	18
Improving Fairness in the Prediction of Heart Failure Length of Stay and Mortality by Integrating Social Determinants of Health	18
Cardiorenal Syndrome: An Evolutionary Appraisal	18
Urinary cGMP (Cyclic Guanosine Monophosphate)/BNP (B-Type Natriuretic Peptide) Ratio, Sacubitril/Valsartan, and Outcomes in Heart Failure With Reduced Ejection Fraction: An Analysis of the PARADIGM-HF	18
Antecedent Flu-Like Illness and Onset of Idiopathic Dilated Cardiomyopathy: The DCM Precision Medicine Study	18
Racial and Social Vulnerability Hotspots in Premature Heart Failure Mortality Across US Counties	18
A Sweet Solution for Heart Failure With Preserved Ejection Fraction: The Role of Sodium-Glucose Cotransporter-2 Inhibitors	18
Quantifying Benefit-Risk Preferences for Heart Failure Devices: A Stated-Preference Study	18
Quantification of Vasoactive Medications and the “Pharmaco-Mechanical Continuum” in Cardiogenic Shock	18
PD-L1 (Programmed Death Ligand 1) as a Marker of Acute Cellular Rejection After Heart Transplantation	17
Clinical Prediction Model for Antibody-Mediated Rejection: A Strategy to Minimize Surveillance Endomyocardial Biopsies After Heart Transplantation	17
Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HF	17
Succinylation of SERCA2a at K352 Promotes Its Ubiquitinoylation and Degradation by Proteasomes in Sepsis-Induced Heart Dysfunction	16
Pulmonary Artery Pressure-Guided Heart Failure Management Reduces Hospitalizations in Patients With Chronic Kidney Disease	16
SGLT2 Inhibitors and Their Effect on Metabolism in Patients With Heart Failure	16
Sex Differences in Skeletal Muscle Pathology in Patients With Heart Failure and Reduced Ejection Fraction	16
Use of Extracorporeal Membrane Oxygenation as Bridge to Replacement Therapies in Cardiogenic Shock: Insights From the Extracorporeal Life Support Organization	16
Mineralocorticoid Receptor Antagonists in Heart Failure: An Update	16
Patient Perceptions and Knowledge Surrounding Pregnancy After Heart Transplantation: A Multicenter Study	16
Comparison of Blood Volume Profiles in Heart Failure With Preserved and Reduced Ejection Fractions: Sex Makes a Difference	16
Unexplained Dyspnea on Exertion: The Difference the Right Test Can Make	16
Sex-Associated Differences in the Clinical Outcomes of Left Ventricular Assist Device Recipients: Insights From Interagency Registry for Mechanically Assisted Circulatory Support	15
Heart Failure Spending Function: An Investment Framework for Sequencing and Intensification of Guideline-Directed Medical Therapies	15
Acute Pulmonary Edema During Impella RP Support: Too Much of a Good Thing	15
Heart Rate Reduction Is Associated With Reverse Left Ventricular Remodeling and Mechanism-Specific Molecular Phenotypes in Dilated Cardiomyopathy	15
Mode of Death in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF Trial	15
Trending Cardiac Biomarkers During Pregnancy in Women With Cardiovascular Disease	15
Nitric Oxide–Mediated Coronary Endothelial Function Is Impaired in Patients With Heart Failure With Preserved Ejection Fraction	15
Edge-to-Edge Transcatheter Mitral Valve Repair Versus Optimal Medical Treatment in Nonresponders to Cardiac Resynchronization Therapy: The MITRA-CRT Trial	15
Outcomes of Combined Heart and Kidney Transplantation Under the New Heart Allocation Policy: A United Organ Network for Organ Sharing Database Analysis	15
Are Men and Women That Different?	15
Safety and Tolerability of Angiotensin Receptor-Neprilysin Inhibitor Initiation in High-Risk Acute Myocardial Infarction Relative to Care Setting: A Subgroup Analysis of the PARADISE-MI Trial	14
Hierarchical End Points in Prior Heart Failure Trials and the HEART-FID Trial	14
Letter by Shah Regarding Article, “Reversible Cause of Heart Failure?”	14
Long-Term Electrocardiographic and Echocardiographic Progression of Arrhythmogenic Right Ventricular Cardiomyopathy and Their Correlation With Ventricular Tachyarrhythmias	14
Myosin-Inhibitor Mavacamten Acutely Enhances Cardiomyocyte Diastolic Compliance in Heart Failure With Preserved Ejection Fraction	14
Case Implementing 2022 AHA/ACC/HFSA Guidelines: Heart Failure Management in Pregnancy: Early Planning, Close Surveillance, and Multidisciplinary Care	14
Ubiquity of Multimorbidity: Comorbid Conditions and Mortality in HFpEF	14
Precision Medicine Is in the Eye of the Beholder	14
Early Outcomes of Heart Transplantation Using Donation After Circulatory Death Donors in the United States	14
Trends and Outcomes Associated With Bariatric Surgery and Pharmacotherapies With Weight Loss Effects Among Patients With Heart Failure and Obesity	14
Conceptualizing Liberation From Venoarterial Extracorporeal Membrane Oxygenation	14
You Are Where You Eat: The Local Environment and Risk of Heart Failure	13
Response by Park et al to Letter Regarding Article, “Transcriptomic Analysis of Right Ventricular Remodeling in Two Rat Models of Pulmonary Hypertension: Identification and Validation of Epithelial-to	13
Late-Life Echocardiographic Effects of the Amyloidogenic p.V142I Transthyretin Variant	13
Proteomic Associations of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) in Heart Failure With Preserved Ejection Fraction	13
Enhanced Expression and Function of Renal SGLT2 (Sodium-Glucose Cotransporter 2) in Heart Failure: Role of Renal Nerves	13
Risk Factors and Outcomes Associated With Heart Failure With Preserved and Reduced Ejection Fraction in People With Chronic Kidney Disease	13
Letter by ten Berg et al Regarding Article, “Early Serial Assessment of Aggregate Vasoactive Support and Mortality in Cardiogenic Shock: Insights From the Critical Care Cardiology Trials Network Regis	13
Combined Loss of Obsc and Obsl1 in Murine Hearts Results in Diastolic Dysfunction, Altered Metabolism, and Deregulated Mitophagy	13
Neurohormonal and Renal Effects of 14-Day Oral Ketone Ester Treatment in Patients With Heart Failure With Reduced Ejection Fraction	13
Pathological Analysis of T1 Pseudonormalization in the Advanced Stage of Female Fabry Cardiomyopathy	12
Disseminated Intracardiac Thrombosis Due to Long-Standing, Asymptomatic Ventricular Fibrillation Under Left Ventricular Assist Device Support	12
Use of a Pulmonary Artery Pressure Sensor to Manage Patients With Left Ventricular Assist Devices	12
Response by Jentzer et al to Letters Regarding Article, “Exposure to Arterial Hyperoxia During Extracorporeal Membrane Oxygenator Support and Mortality in Patients With Cardiogenic Shock”	12
Response by Glargaard et al to Letter Regarding Article, “Pleural Effusion and Invasive Hemodynamic Measurements in Advanced Heart Failure”	12
Impact of Heart Transplant Allocation Change on Waitlist Mortality and Posttransplant Mortality in Patients With Left Ventricular Assist Devices	12
Continuous-Flow Intra-Aortic Percutaneous Mechanical Circulatory Support in Heart Failure With Worsening Renal Function	12
Diuretic Changes, Health Care Resource Utilization, and Clinical Outcomes for Heart Failure With Reduced Ejection Fraction: From the Change the Management of Patients With Heart Failure Registry	12
Quality of Life and Exercise Capacity in Early Stage and Subclinical Hypertrophic Cardiomyopathy: A Secondary Analysis of the VANISH Trial	11
Editors and Editorial Board	11
Myocardial DNA Damage Is Responsible for the Relationship Between Genotype and Reverse Remodeling in Patients With Dilated Cardiomyopathy	11
Correction to: Response to Letter Regarding Article “Characterizing Gender Differences in Physical Frailty Phenotypes in Heart Failure”	11
Iron Deficiency, Anemia, and Iron Supplementation in Patients With Heart Failure: A Population-Level Study	11
Acute Heart Failure Caused by Rupture of Sinus of Valsalva Into Right Atrium in a Patient With Possible Infective Endocarditis After Tricuspid Annuloplasty: A Misdirected Clinical Decision-Making	11
Iron Deficiency Induces Heart Failure With Ectopic Cardiac Calcification in Mice With Metabolic Syndrome	11
Long-Term Trajectories of Left Heart Geometry, Mechanics, and Oxygen Demand After Bariatric Surgery	10

Correction to: Targeted Gene Deletion or Antagonism of the Prostaglandin E2 EP3 Receptor Protects Against Cardiac Injury Postmyocardial Infarction	10
Atrial Septal Defect, Pulmonary Arterial Hypertension, and Diastolic Left Heart Failure: When 3 Players Come into the Game	10
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial	10
Does Aspirin Prevent Incident Heart Failure in Healthy Older Adults? Examining the Evidence From the ASPREE Trial	10
Combining Minimally Invasive Surgery With Ultra-Fast-Track Anesthesia in HeartMate 3 Patients: A Pilot Study	10
Association of Lifestyle With Incidence of Heart Failure According to Metabolic and Genetic Risk Status: A Population-Based Prospective Study	10
Clinician and Algorithmic Application of the 2019 and 2022 Society of Cardiovascular Angiography and Intervention Shock Stages in the Critical Care Cardiology Trials Network Registry	10
Exception Status Listing in the New Adult Heart Allocation System: A New Solution to an Old Problem?	10
Transfusions in Heart Failure and Acute Myocardial Infarction: Novel Data Begets New Questions	10
Musclin and HFpEF: Unlocking Skeletal Muscle Potential to Improve Exercise Tolerance	10
A Composite Score Summarizing Use and Dosing of Evidence-Based Medical Therapies in Heart Failure: A Nationwide Cohort Study	10
Intermittent Occlusion of the Superior Vena Cava to Improve Hemodynamics in Patients With Acutely Decompensated Heart Failure: The VENUS-HF Early Feasibility Study	10
Editors and Editorial Board	9
FGF21 (Fibroblast Growth Factor 21) Defines a Potential Cardiohepatic Signaling Circuit in End-Stage Heart Failure	9
First In-Man Experience With TricValve Transcatheter Bicaval Valve System in Left Ventricular Assist Device Heartmate II Patient for High-Risk Tricuspid Regurgitation	9
TAVI With ACURATE neo2 Valve in Aortic Regurgitation Due to Left Ventricular Assist Device: A Custom-Made Option	9
Epidemiology and Outcomes of Aortic Stenosis in Acute Decompensated Heart Failure: The ARIC Study	9
The Future of Mechanical Circulatory Support	9
Response by Shah et al to Letter Regarding Article, “False-Positive ^99m Technetium-Pyrophosphate Scintigraphy in Two Patients With Hypertrophic Cardiomyopathy”	9
Letter by Bonaventura and Tangianu Regarding Article, “Pleural Effusion and Invasive Hemodynamic Measurements in Advanced Heart Failure”	9
Grace Under Pressure	9
Access to Heart Failure Medicines in Low- and Middle-Income Countries: An Analysis of Essential Medicines Lists, Availability, Price, and Affordability	9
Management and Outcomes of Acute Myocardial Infarction-Cardiogenic Shock in Uninsured Compared With Privately Insured Individuals	9
Potential Novel Therapeutic Target to Improve Graft Survival: New Insights Into the Role of Checkpoint Molecules in Heart Transplant Rejection	8
Sodium Restriction in Patients With Heart Failure: A Systematic Review and Meta-Analysis of Randomized Clinical Trials	8
Untangling the Sex-Frailty Paradox in Heart Failure	8
Empagliflozin Improves Diastolic Function in HFpEF by Restabilizing the Mitochondrial Respiratory Chain	8
Acute Hemodynamic Effects and Tolerability of Phosphodiesterase-1 Inhibition With ITI-214 in Human Systolic Heart Failure	8
Fibrotic Plaque and Microvascular Dysfunction Predict Early Cardiac Allograft Vasculopathy Progression After Heart Transplantation: The Early Post Transplant Cardiac Allograft Vasculopathy Study	8
Physiologic Insights Into Long COVID Breathlessness	8
SGLT2 (Sodium-Glucose Cotransporter-2) Inhibitor–Mediated Blunting of Blood Volume Redistribution: A Candidate Mechanism for Attenuating Cardiac Filling Pressures and Exercise Intolerance in Heart Fai	8
Comprehensive Transcriptomics Profiling of MicroRNA Reveals Plasma Circulating Biomarkers of Hypertrophic Cardiomyopathy and Dysregulated Signaling Pathways	8
Natriuresis-Guided Titration of Loop Diuretics in Heart Failure: Another Brick in the Wall	8
Estrogen Protects Cardiac Function and Energy Metabolism in Dilated Cardiomyopathy Induced by Loss of Cardiac IRS1 and IRS2	8
Systemic Circulation in Advanced Heart Failure and Cardiogenic Shock: State-of-the-Art Review	8
Patient-Specific Computational Fluid Dynamics Reveal Localized Flow Patterns Predictive of Post–Left Ventricular Assist Device Aortic Incompetence	8
Musclin Counteracts Skeletal Muscle Dysfunction and Exercise Intolerance in Heart Failure With Preserved Ejection Fraction	8
Effect of Empagliflozin on Multiple Biomarkers in Heart Failure: Insights From the Empire Heart Failure Trial	8
Alcohol Intake in Patients With Cardiomyopathy and Heart Failure: Consensus and Controversy	8
Lactobacillus Restructures the Micro/Mycobiome to Combat Inflammation-Mediated Right Ventricular Dysfunction in Pulmonary Arterial Hypertension	8
Endothelial Stromal PD-L1 (Programmed Death Ligand 1) Modulates CD8 ⁺ T-Cell Infiltration After Heart Transplantation	8
Serial ^99m Technetium Pyrophosphate Scintigraphy and Multimodality Assessments After Different Doses of Tafamidis for Variant Transthyretin Cardiac Amyloidosis	7
Proteomic Biomarkers of Sacubitril/Valsartan Treatment Response in Heart Failure With Preserved Ejection Fraction: Molecular Insights Into Sex Differences	7
Background Medical Therapy and Clinical Outcomes From the VICTORIA Trial	7
Social Determinants of Health and Disparities in Guideline-Directed Medical Therapy Optimization for Heart Failure	7
Ramping Up the Pressure on the Right Ventricle	7
Hemodynamic Effects of Cyclic Guanosine Monophosphate-Dependent Signaling Through β3 Adrenoceptor Stimulation in Patients With Advanced Heart Failure: A Randomized Invasive Clinical Trial	7
Temporal Trends and Prognosis of Physical Examination Findings in Patients With Acute Decompensated Heart Failure: The ARIC Study Community Surveillance	7
Physical Activity, Sedentary Time, and Heart Failure Risk in Low-Income Black and White Adults Living in the Southeastern United States	7
Response by Liang and Shimada to Letter Regarding Article “Comprehensive Proteomics Profiling Reveals Circulating Biomarkers of Hypertrophic Cardiomyopathy”	7
Response by Colin-Ramirez et al to Letter Regarding Article, “Sodium Restriction in Patients With Heart Failure: A Systematic Review and Meta-Analysis of Randomized Clinical Trials”	7
Left Atrial Reverse Remodeling in Patients Supported With Durable Left Ventricular Assist Devices and Clinical Implications	7
Proteomic Analysis of Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Clinical Trial	6
Association of Patient Reported Outcomes With Caregiver Burden in Older Patients With Advanced Heart Failure: Insights From the SUSTAIN-IT Study	6
Pleural Effusion and Invasive Hemodynamic Measurements in Advanced Heart Failure	6
Cardiogenic Shock Teams: Past, Present, and Future Directions	6
Letter by Monda and Limongelli Regarding Article, “Changes in Cardiac Function Following Fulminant Myocarditis”	6
Management of Hypertension in Patients With Ventricular Assist Devices: A Scientific Statement From the American Heart Association	6
Practical Guide on the Use of Induction Immunosuppression in Heart Transplantation	6
Is My Patient Fit for Surgery? Navigating Between the Rock of Heart Failure and the Hard Place of Semiurgent Surgery	6
Rare Etiology of Cardiogenic Shock in Pregnancy	6
Impact of Blood Pressure Targets in Patients With Heart Failure Undergoing Postresuscitation Care: A Subgroup Analysis From a Randomized Controlled Trial	6
How Did We Score? Evaluating the Utility of a Score-Based System for Heart Failure Medical Therapy	6
Adverse Outcomes Associated With Interleukin-6 in Patients Recently Hospitalized for Heart Failure With Preserved Ejection Fraction	6
Letter by Dalzell and Cannon Regarding Article, “Pitfalls in the World of Evidence-Based Medicine: Should IABP Be en-DANGER-ed by the DanGer Shock Trial?”	6
In-Hospital Virtual Peer-to-Peer Consultation to Increase Guideline-Directed Medical Therapy for Heart Failure: A Pilot Randomized Trial	6
Is It Primetime for Finerenone in Heart Failure?	6
Effect of Dapagliflozin on Accelerometer-Based Measures of Physical Activity in Patients With Heart Failure: An Analysis of the DETERMINE Trials	6
Association Between Angiotensin Receptor–Neprilysin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection Fraction	6
Correction to: Diagnosis and Treatment of Right Heart Failure in Pulmonary Vascular Diseases: A National Heart, Lung, and Blood Institute Workshop	6
Clinical Management and Transplant Considerations in Pediatric Pulmonary Hypertension Due to Left Heart Disease: A Scientific Statement From the American Heart Association	6
Impact of Rapid Up-Titration of Guideline-Directed Medical Therapies on Quality of Life: Insights From the STRONG-HF Trial	5
Get With the Guidelines-Heart Failure: Twenty Years in Review, Lessons Learned, and the Road Ahead	5
Racial Differences in Donor-Derived Cell-Free DNA and Mitochondrial DNA After Heart Transplantation, on Behalf of the GRAfT Investigators	5
Long-Term Trajectories of Left Ventricular Ejection Fraction in Patients With Chronic Inflammatory Diseases and Heart Failure: An Analysis of Electronic Health Records	5
Closing the Gap Between Populations Enrolled in Traditional Randomized Controlled Trials and Patients Encountered in Clinical Practice	5
Trimethylamine N -Oxide and Related Gut Microbe-Derived Metabolites and Incident Heart Failure Development in Community-Based Populations	5
Eosinophilic Myocarditis in a Patient With Systemic Lupus Erythematosus and P-Neutrophil Cytoplasmic Antibodies Associated Vasculitis Overlap	5
Is There a Logic in Using Device-Based Algorithms to Prevent Heart Failure Decompensations?	5
Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Trials	5
Enhancing the Prediction of Cardiac Allograft Vasculopathy Using Intravascular Ultrasound and Machine Learning: A Proof of Concept	5
AHA/ACC/HFSA Guidelines Implementation Case Series: Resynchronization Pacing Preferred in Patients With Reduced Ejection Fraction	5
Outcomes With Phosphodiesterase-5 Inhibitor Use After Left Ventricular Assist Device: An STS-INTERMACS Analysis	5
Letter by Kambic et al Regarding Article, “A Randomized, Controlled Trial of Resistance Training Added to Caloric Restriction Plus Aerobic Exercise Training in Obese Heart Failure With Preserved Eject	5
Prediction of Donor Heart Acceptance for Transplant and Its Clinical Implications: Results From The Donor Heart Study	5
Differential Outcomes for Women and Men With Advanced Heart Failure Therapies: Sex Matters	5
Cannabis Use and Heart Transplantation: Disparities and Opportunities to Improve Outcomes	5
Metabolic Profiling Identifies 1-MetHis and 3-IPA as Potential Diagnostic Biomarkers for Patients With Acute and Chronic Heart Failure With Reduced Ejection Fraction	5
Hepatopulmonary Syndrome or Portopulmonary Hypertension? Two Contrasting Cases of Exertional Hypoxemia From Liver Disease	5
Reviving the Swan: Presenting the Chicago Hemodynamic Forum	5
Response by Elliott et al to Letter Regarding Article, “Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy”	5
A Rising Tide (Unfortunately) Lifts All Boats: Elucidating the Relationship Between Cardiac Filling Pressures and Pleural Effusions	5
Multiparametric Implantable Cardioverter-Defibrillator Algorithm for Heart Failure Risk Stratification and Management: An Analysis in Clinical Practice	4
FGF-23 (Fibroblast Growth Factor-23) and Cardiorenal Interactions	4
Sex-Specific Outcomes of Candidates Listed as the Highest Priority Status for Heart Transplantation	4